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Summary
Background:  Some  patients  with  non-small-cell  lung  cancer  (NSCLC)  respond  well  to  the  EGFR
tyrosine  kinase  inhibitor  geﬁtinib.  Chinese  herbal  medicine  (CHM)  was  effective  in  improving
the quality  of  life  and  prolonging  overall  survival  in  patient  with  NSCLC.  We  aim  to  determine
whether geﬁtinib  plus  CHM  could  prolong  the  progression-free  survival  (PFS)  or  median  survival
time (MST)  in  patients  with  NSCLC  than  geﬁtinib  alone.
Methods:  We  retrospectively  analyzed  159  non-small-cell  lung  cancer  patients  with  the
method of  retrospective  case—control  study,  matching  factors  included  gender,  age  categories
(30—39,40—49,50—59,60—69,70—79),  pathological  stage  (IIIB  or  IV),  smoking  status  (never:
<100 lifetime  cigarettes,  or  ever:  ≥100  lifetime  cigarettes),  pathology,  and  performance  sta-
tus. Among  the  159  patients,  100  patients  treated  with  geﬁtinib  (250  mg/day  orally)  plus  CHM
(‘‘Fuzheng Kang’ai’’  decoction,  a  Chinese  herbal  medicine,  250  ml/bid/day  orally),  59  patients
treated with  geﬁtinib  (250  mg/day  orally)  only.  PFS  and  MST  were  analyzed  for  the  whole
population.
Results: 58  pairs  were  matched  successfully.  1  patient  (treated  with  geﬁtinib)  with  the  age  of
27 years  failed  to  be  matched.  Progression-free  survival  was  signiﬁcantly  longer  in  patients
treated with  geﬁtinib  plus  CHM  than  with  geﬁtinib:  median  PFS  was  13.1  months  (95%  CI
6.50—19.70)  with  geﬁtinib  plus  CHM  versus  11.43  months  (95%  CI  7.95—14.91)  with  geﬁtinib
(log-rank  P  =  0.013).  Median  overall  survival  was  longer  with  geﬁtinib  plus  CHM  than  with  geﬁt-
inib: median  MST  was  22.83  months  (95%  CI  17.51—28.16)  with  geﬁtinib  plus  CHM  versus  18.7
months (95%  CI  16.83—20.57)  with  geﬁtinib  (log-rank  P  =  0.049).  The  most  common  adverse
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event  was  rash,  the  incidence  in  the  geﬁtinib  plus  CHM  group  was  41.38%  while  in  the  geﬁtinib
group was  24.14%  (P  =  0.048).
Conclusions:  This  case—control  analysis  suggested  that  treatment  with  geﬁtinib  plus  CHM  pro-
longed PFS  and  MST  compared  with  geﬁtinib  in  patients  with  NSCLC,  and  it  is  worthy  of  further
study.
© 2014  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC
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(Burk.)  F.  H.  Chen  (Sanqi),  Eclipta  prostrate  L.  (Hanliancao),
Bletilla  striata  (Thunb.)  Reichb.  f.  (Baiji)  or  YunNanBaiYao
were  selected;  for  high  fever,  Bubalus  bubalis  L.  (Shuiniu-BY-NC-ND  license  (http://cre
Background
Lung  cancer  is  the  leading  cause  of  cancer-related  mor-
tality  worldwide.1 Non-small  cell  lung  cancer  (NSCLC)  is
the  most  common  form,  and  many  patients  present  with
advanced  disease  at  initial  diagnosis.  Platinum-based  dou-
blet  chemotherapy  is  still  the  standard  therapy  for  NSCLC.
However,  the  response  rate  of  chemotherapy  is  only  20—35%,
and  median  overall  survival  is  about  6.9—11.3  months.2,3
Recent  advances  in  targeted  therapy  provided  a  new
treatment  option  for  non-small  cell  lung  cancer.  As  the
representative  of  ﬁrst  generation  epidermal  growth  factor
receptor  tyrosine  kinase  inhibitor  (EGFR-TKI),  geﬁtinib  pro-
longed  progression-free  survival  and  improved  quality  of
life  compared  with  platinum-based  doublet  chemotherapy
in  patients  with  NSCLC  whose  tumors  have  activating  epi-
dermal  growth  factor  receptor  (EGFR)  mutations.4—6 The
response  rate  of  EGFR-TKI  in  patients  with  EGFR  mutations
is  about  70—80%.7—9 Despite  the  high  response  rate,  the
development  of  secondary  resistance  in  10  —14  months  after
treatment  inevitably  leads  to  treatment  failure.10
Chinese  Herbal  Medicine  (CHM)  has  been  used  for
thousands  of  years,  some  studies  reported  that  CHM  may
reduce  the  occurrence  of  adverse  reactions  such  as  ane-
mia  and  neutropenia.11 CHM  may  also  improve  the  quality  of
life,  reduce  recurrence  rate  and  prolonging  overall  survival,
etc.12
In  previous  clinical  practice,  we  found  that  CHM  could
improve  therapeutic  efﬁcacy  of  geﬁtinib.  In  this  study,
we  assessed  whether  geﬁtinib  plus  CHM  could  prolong  the
progression-free  survival  (PFS)  or  median  survival  time  (MST)
in  patients  with  NSCLC  than  geﬁtinib  alone.
Methods
Patients
We  retrospectively  analyzed  159  NSCLC  patients  treated
with  geﬁtinib  plus  CHM  or  geﬁtinib  from  July  2007  to
December  2012.  100  patients  treated  with  geﬁtinib  plus
CHM  were  from  Guangdong  Provincial  Hospital  of  Traditional
Chinese  Medicine,  and  59  patients  with  geﬁtinib  from  Guang-
dong  Provincial  Peoples  Hospital.
Case—control  procedure
There  may  be  a  signiﬁcant  bias  between  patients  who
were  treated  with  geﬁtinib  plus  CHM  or  geﬁtinib.  There-
fore,  we  used  a  matching  procedure  on  the  computer,
which  eliminated  biases  as  much  as  possible,  to  match  all
the  patients  by  gender,  age,  smoking  status,  performance
j
s
Gcommons.org/licenses/by-nc-nd/3.0/).
tatus  (PS)  and  pathological  factors.  These  factors  were
elected  because  they  are  closely  associated  with  survival
n  NSCLC  patients.13 Matching  factors  included  sex,  age
ategories  (30—39,40—49,50—59,60—69,70—79),  pathologi-
al  stage  (IIIB  or  IV),  smoking  status  (never:  <100  lifetime
igarettes,  or  ever:  ≥100  lifetime  cigarettes),  pathology,
nd  performance  status.
nterventions
atients  in  geﬁtinib  plus  CHM  group  treated  with  geﬁtinib  (G,
50  mg/day  orally)  plus  CHM  (250  ml/bid/day  orally),  while
n  control  group  only  treated  with  geﬁtinib  (250  mg/day
rally).  Geﬁtinib  or  CHM  was  administered  until  progression
f  the  disease,  or  development  of  unacceptable  toxicities.
hinese  herbal  medicine
hinese  herbal  medicine,  which  called  ‘‘Fuzheng  Kan-
ai’’(FZKA  for  short)  decoction,  prescribed  by  professor
u  Wanyin  in  Guangdong  Provincial  Hospital  of  Traditional
hinese  Medicine,  consisted  of  Pseudostellaria  hetero-
hylla  (Miq.)  Pax  ex  Pax  et  Hoffm.  (Taizishen)  30  g,
tractylodes  macrocephala  Koidz.  (Baizhu)  15  g,  Astragalus
embranaceus  (Fisch.)  Bge.  (Huangqi)  30  g,  Oldenlandia
iffusa  (Willd.)  Roxb.  (Baihuasheshecao)  30  g,  Solanum
igrum  L.  (Longkui)  30  g,  Salvia  chinensis  Benth  (Shi-
ianchuan)  30  g,  Cremastra  appendiculata  (D.  Don)  Makino
Shancigu)  30  g,  Coix  lachrymal-jobi  L.  (Yiyiren)  30  g.  Akebia
uinata  (Thunb.)  Decne  (Bayuezha)  30  g,  Rubus  parviﬂolius
.  (Shepaole)  30  g.  Curcuma  kwangsiensis  S.G.  Lee  et  C.F.
iang  (Ezhu)  15  g,  Glycyrrhiza  uralensis  Fisch.  (Gancao)  10  g.
Further  adjustments  were  made  based  on  the  spe-
iﬁc  symptoms  presenting  on  patients.  For  chest  and  back
ain,  Aconitum  carmichaeli  Debx.  (Chuanwu),  Corydalis
urtschaninovii  Bess.  F.  yanhusuo  Y.  H.  Chou  et  C.  C.  Hsu
Yanhusuo),  Angelica  dahurica  Benth.  Et  Hook.  (Baizhi),
ommiphora  myrrha  Engl.  (Moyao)  were  selected;  for  pleu-
al  effusion,  Phytolacca  acinosa  Roxb.  (Shanglu),  Descurania
ophia  (L.)  Schur.  (Tinglizi),  Plantago  asiatica  L.  (Cheqian-
ao)  and  Ziziphus  jujube  Mill.  Var.  inermis  (Bge.)  Rehd.
Dazao)  were  added;  for  hemosputum,  Imperata  cylindrical
L.)  Beauv.  Var.  major  (Nees.)  C.  E.  Hubb.  (Baimao-
en),  Nelumbo  nucifera  Gaertn.  (Oujie),  Panax  notoginsengiao),  Isatis  tinctoria  L.  (Daqingye),  Cypsum  (Shigao),  were
elected.14
All  of  the  above  herbal  medicines  were  provided  by
uangdong  Kangmei  Pharmaceutical  Company  Ltd.  The
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reparation  method  of  FZKA  decoction  was  as  follows:  the
erbs  were  put  in  a  pot  (metallic  pots  were  prohibited),
uitable  amount  of  water  (the  water  level  should  be  above
edicine  surface  for  2  cm,  about  1000  ml)  was  added  and  the
erbs  were  soaked  for  30  min.  The  herbs  were  brought  to  boil
n  high  heat  (Wuhuo),  and  followed  by  low  heat  (Wenhuo)
ntil  around  250  ml  of  decoction  was  resulted.  The  decoc-
ion  was  poured  out  and  is  now  ready  for  use;  750  ml  of  water
as  added  to  the  herbal  mixture  and  brought  to  boil  again
or  the  second  time.  Another  250  ml  of  decoction  was  then
esulted.  The  2  doses  of  decoction  were  mixed,  divided  into
 equal  portions  and  taken  warm,  twice  a  day.
tatistical  analysis
rogression-free  survival  (PFS)  was  deﬁned  as  the  time  span
etween  the  date  of  treatment  to  the  earliest  sign  of  disease
rogression  as  determined  by  CT  or  MRI  according  to  RECIST
riteria,15 or  death  from  any  cause.  Median  survival  time
MST)  was  deﬁned  as  the  time  from  the  date  of  treatment
o  the  date  of  death.  Safety  and  tolerability  were  assessed
ccording  to  National  Cancer  Institute  Common  Terminol-
gy  Criteria  for  Adverse  Events,  version  3.0.PFS  and  MST
ere  analyzed  by  using  the  Kaplan—Meier  method,  and  were
ompared  using  the  log-rank  test.  Baseline  characteristics
ere  analyzed  using  either  two-sample  t  tests  or  Wilcoxon
ank  sum  tests  for  continuous  data,  and  Chi-squared  tests
r  Fisher’s  exact  tests  for  categorical  data  were  conducted
fter  the  test  for  normality.  A  signiﬁcance  level  of  5%  was
sed  throughout  the  analysis.  The  incidence  rates  of  adverse
vents  were  compared  with  the  use  of  Fisher’s  exact  tests.
ll  statistical  analysis  was  done  with  the  SPSS  16.0  statistical
ackage.
esults
atient  characteristics
8  pairs  were  matched  successfully,  one  27-year  old  patient
reated  with  geﬁtinib  failed  to  be  matched  because  of  the
ge.  Among  the  116  patients,  58  patients  with  the  treat-
ent  of  geﬁtinib  plus  CHM  and  58  patients  with  the  single
rug  treatment  of  geﬁtinib  (control  group).  The  base-line
haracteristics  of  patients  are  given  in  Table  1.
isease  progression-free  survival  (PFS)
he  median  progression-free  survival  was  signiﬁcantly
onger  in  patient  treated  with  geﬁtinib  plus  CHM  than  with
eﬁtinib:  median  PFS  was  13.1  months  (95%  CI  6.50—19.70)
ith  geﬁtinib  plus  CHM  versus  11.43  months  (95%  CI
.95—14.91)  with  geﬁtinib  (log-rank  P  =  0.013)(Fig.  1A,
able  2).  In  the  ﬁrst-line  treatment,  the  median  PFS  of
he  geﬁtinib  plus  CHM  group  and  geﬁtinib  group  was  12.33
onths  and  11.43  months,  respectively  (P  =  0.024)  (Fig.  1B,
able  2).  Subgroup  analyses  were  performed  to  compare  PFS
etween  treatments  in  groups  deﬁned  according  to  EGFR
ene  status,  gender,  smoking  status  and  the  pathologic  types
Table  2).  The  PFS  of  the  geﬁtinib  plus  CHM  group  was  25.2
onths  and  geﬁtinib  group  was  11.80  months  in  patients
a
t
a
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ith  EGFR  mutations  (exon  19  deletions  or  21  exon  muta-
ion)  (P  =  0.016)  (Fig.  1C,  Table  2).  PFS  in  geﬁtinib  plus  CHM
as  12.10  months  while  in  geﬁtinib  group  was  11.43  months
or  the  female  patients  (P  =  0.020)  (Fig.  1D,  Table  2).  Simi-
arly,  PFS  of  geﬁtinib  plus  CHM  group  was  13.10  months  and
eﬁtinib  group  was  11.80  months  in  never  smoked  (P  =  0.007)
Fig.  1E,  Table  2)  and  adenocarcinoma  patients  (P  =  0.022)
Fig.  1F,  Table  2).
edian  survival  time  (MST)
he  median  overall  survival  was  longer  with  geﬁtinib  plus
HM  than  with  geﬁtinib:  median  MST  was  22.83  months  (95%
I  17.51—28.16)  with  geﬁtinib  plus  CHM  versus  18.7  months
95%  CI  16.83—20.57)  with  geﬁtinib  (log-rank  P  =  0.049)
Fig.  2A,  Table  3).  In  the  ﬁrst-line  treatment,  no  signif-
cant  difference  of  MST  was  observed  between  geﬁtinib
lus  CHM  and  geﬁtinib  groups  (P  =  0.084)  (Fig.  2B,  Table  3).
ubgroup  analyses  were  performed  to  compare  the  median
urvival  time  between  treatments  in  groups  deﬁned  accord-
ng  to  EGFR  gene  status,  gender,  smoking  status  and  the
athologic  types  (Table  3).  The  MST  of  the  geﬁtinib  plus
HM  group  was  23.73  months  and  geﬁtinib  group  was  20.27
onths  in  patients  whose  EGFR  gene  statuses  were  unknown
P  =  0.018)  (Fig.  2C,  Table  3).  MST  of  geﬁtinib  plus  CHM
as  23.73  months  and  geﬁtinib  group  was  18.70  months  in
emale  patients  (P  =  0.027)  (Fig.  2D,  Table  3).  MST  in  geﬁti-
ib  plus  CHM  group  was  23.73  months  and  geﬁtinib  group  was
8.87  months  in  never  smoked  patients  (P  =  0.044)  (Fig.  2E,
able  3).  However,  MST  of  geﬁtinib  plus  CHM  was  22.83
onths  and  geﬁtinib  group  was  18.87  months  in  adenocar-
inoma  patients  (P  =  0.065)  (Fig.  2F,  Table  3).
dverse  events
he  most  common  adverse  events  were  rash  and  diarrhea
Table  4).  The  second  were  stomatitis  and  aminotransferase
levation.  The  incidence  of  rash  in  G  group  was  41.38%,
hile  in  GF  group  was  24.14%.  The  incidence  of  rash  in  GF
roup  was  statistically  lower  than  that  in  G  group  (P  =  0.048).
iscussion
eﬁtinib,  as  a  member  of  the  ‘‘small  molecule’’  tyrosine
inase  inhibitors  (TKI),16,17 is  a  standard  ﬁrst-line  treat-
ent  for  NSCLC  patients  with  EGFR  mutation.  Several
andomized  phase  III  trials  demonstrated  that  geﬁti-
ib  prolonged  progression-free  survival  and  improved
uality  of  life  compared  with  platinum-based  doublet
hemotherapy.4—6 However,  the  development  of  secondary
esistance  inevitably  leads  to  treatment  failure  (in  the  most
ecent  studies  for  up  to  10—14  months).10 The  most  com-
on  molecular  mechanisms  of  secondary  resistance  are
reonine-to-methionine  amino  acid  change  at  position  790
T790M)  of  the  EGFR  kinase  domain  (found  in  50%  of  cases)
nd  MET  ampliﬁcation  (found  in  up  to  20%  cases).18,19 Some
gents  were  designed  to  overcome  the  secondary  resis-
ance,  such  as  afatinib,  which  is  an  irreversible  inhibitor
gainst  all  EGFR  family  members  and  T790M  mutation,20 has
lso  demonstrated  to  be  superior  to  chemotherapy  in  EGFR
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Table  1  Patient  base-line  characteristics.
Characteristic  Geﬁtinib  plus  CHM  (N  =  58)  Geﬁtinib  (N  =  58)  P  value
Sex—–no.  (%)  1
Male 22  (37.9)  22  (37.9)
Female 36  (62.1)  36  (62.1)
Age—–yr 0.615
Mean 60.0  ±  10.31  59.47  ±  11.02
Range 33—82  33—85
Smoking  status—–no.  (%) 1
Never  smoked 38  (65.5) 38  (65.5)
Previous or  current  smoker 20  (34.5) 20  (34.5)
ECOG performance  status  score—–no.  (%) 1
0  4  (6.9)  4  (6.9)
1 48  (82.8)  48  (82.8)
2 5  (8.6)  5  (8.6)
3 1  (1.7)  1  (1.7)
Histologic  diagnosis—–no.  (%)  1
Adenocarcinoma  54  (93.1)  54  (93.1)
Squamous-cell  carcinoma  2  (3.4)  2  (3.4)
Adenosquamous  carcinoma  2  (3.4)  2  (3.4)
Large-cell  carcinoma  0  0
Other 0  0
Clinical  stage—–no.  (%)  1
IIIB 2(3.4)  2(3.4)
IV 56(96.6)  56(96.6)
Therapy  line  (geﬁtinib) 1
1st  line  25  (43.1)  25  (43.1)
2nd line  23  (39.7)  23  (39.7)
≥3rd line  10  (17.2)  10  (17.2)
Type of  EGFR  mutation—–no.  (%) 1.89E−10
Exon  18  mutation 1(1.7)  0
Exon 19  deletion 2  (3.4)  22  (37.9)
Exon 20  mutation 1  (1.7) 2  (3.4)
Exon 21  mutation 2  (3.4) 19  (32.8)
Negative 5  (8.6) 4  (6.9)
Unknown  47  (81.0) 11  (19.0)
Table  2  Progression-free  survival  of  subgroups  (months).
Subgroup  Geﬁtinib  plus  CHM  Geﬁtinib  P  value
Whole  population  13.1  11.43  0.013
Therapy line  (geﬁtinib)
1st  line  12.33  11.43  0.024
2nd line  12.1  12.7  0.567
EGFR stutas
Mutation  25.2  11.8  0.016
Unknown 13.0  13.43  0.147
Gender
Male 18.37  13.13  0.593
Female 12.0  11.43  0.009
Smoking status
Never  smoked  13.1  11.8  0.007
Previous or  current  smoker  17.13  10.73  0.637
Pathologic types
Adenocarcinoma  13.1  11.8  0.022
Squamous-cell  carcinoma  —  —
Adenosquamous  carcinoma  —  —
—: The number of patients was only two, we did not conduct statistical analysis.
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Figure  1  Kaplan—Meier  curves  for  progression-free  survival  in  patients  of  whole  population  (A),  patients  of  ﬁrst-line  treatment
(B), patients  with  EGFR  mutations  (exon  19  deletions  or  21  exon  mutation)  (C),  female  patients  (D),  never  smoked  patients  (E),
adenocarcinoma  patients  (F).
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Figure  2  Kaplan—Meier  curves  for  median  overall  survival  in  patients  of  whole  population  (A),  patients  of  ﬁrst-line  treatment  (B),
patients whose  EGFR  mutations  unknown  (C),  female  patients  (D),  never  smoked  patients  (E),  adenocarcinoma  patients  (F).
1016  X.-B.  Yang  et  al.
Table  3  Median  survival  time  of  subgroups  (months).
Subgroup  Geﬁtinib  plus  CHM  Geﬁtinib  P  value
Whole  population  22.83  18.7  0.049
Therapy line  (geﬁtinib)
1st  line  25.33  18.7  0.084
2nd line 20.3  22.03  0.884
EGFR stutas
Mutation  15.2 17.77 0.566
Unknown  23.73 20.27 0.018
Gender
Male  20.7  19.33  0.593
Female 23.73  18.7  0.009
Smoking status
Never  smoked  23.73  18.87  0.044
Previous or  current  smoker  20.7  18.2  0.80
Pathologic types
Adenocarcinoma  22.83  18.87  0.065
Squamous-cell  carcinoma  —  —
Adenosquamous  carcinoma  —  —
—: The number of patients was only two, we did not conduct statistical analysis.
Table  4  Common  toxic  effects  in  the  safety  population.
Toxic  effect  Geﬁtinib  plus  FZKA  (N  =  30)  number
(percent)
Geﬁtinib  (N  =  30)  number
(percent)
P  value
Grade  1  Grade  2  Grade  3  Grade  4  Grade  1  Grade  2  Grade  3  Grade  4
Rash  12  (20.7)  1  (1.7)  1  (1.7)  0  19  (32.8)  4  (6.9)  1  (1.7)  0  0.048
Diarrhea 2  (3.4)  1  (1.7)  0  0  3  (5.2)  1  (1.7)  0  0  0.671
Stomatitis 1  (1.7)  0  0  0  2  (3.4)  0  0  0  0.783
Nausea 0  0  0  0  0  0  0  0
Vomiting 0  0  0  0  0  0  0  0
Aminotransferase
elevation
1 (1.7)  0  0  0  2  (3.4)  0  0  0  0.783
Neutropenia 0  0  0  0  0  0  0  0
Anemia 0  0  0  0  0  0  0  0
Pneumonitis  0  0  0  0  0  0  0  0
mmo
m
A
a
m
n
C
c
C
d
C
t
m
N
n
p
F
c
t
g
y
t
g
t
i
E
M
g
s
o
m
iToxic-effect grades are based on the National Cancer Institute Co
utated  patients.21,22 MET  inhibitors,  such  as  MetMAb  and
RQ197  (tivantinib),  are  currently  in  clinical  development
nd  had  showed  some  clinical  beneﬁt.23,24
Complementary  alternative  medicine  (CAM)  is  becoming
ore  and  more  popular  all  over  the  world,25 traditional  Chi-
ese  medicine  (TCM)  is  an  important  part  of  CAM.  In  China,
hinese  herb  medicine  (CHM)  is  the  most  commonly  used
ategory  of  TCM.26,27 Several  studies  reported  that  some
HMs  like  honokiol  and  Scutellaria  baicalensis, as  well  as
ecoctions  like  anticancer  number  one  (ACNO,  a 19-herb
hinese  formula  used  to  treat  cancer  patients),  have  poten-
ial  anticancer  effects  in  vitro  or  in  vivo  studies.28—30
‘‘Fuzheng  Kangai’’(FZKA)  decoction,  a  Chinese  herbal
edicine  prescribed  at  the  clinic,  has  been  used  to  treat
SCLC  in  Guangdong  Provincial  Hospital  of  Traditional  Chi-
ese  Medicine  for  more  than  10  years.  In  previous  clinical
ractice,  we  found  that  the  efﬁcacy  of  geﬁtinib  plus
ZKA  was  better  than  geﬁtinib  alone.  This  retrospective
l
t
mn Terminology Criteria (version 3.0).
ase—control  study  showed  that  the  PFS  and  MST  were  bet-
er  in  NSCLC  patients  of  whole  population  treated  with
eﬁtinib  plus  CHM  (FZKA)  than  with  geﬁtinib.  Subgroup  anal-
ses  were  performed  to  compare  PFS  and  MST  between
reatments  in  groups  deﬁned  according  to  EGFR  gene  status,
ender,  smoking  status  and  the  pathologic  types.  The  PFS  of
he  geﬁtinib  plus  CHM  group  was  longer  than  geﬁtinib  group
n  female,  never  smoked,  adenocarcinoma  patients  with
GFR  mutations  (exon  19  deletions  or  21  exon  mutation).
ST  in  geﬁtinib  plus  CHM  group  was  longer  than  geﬁtinib
roup  in  female,  never  smoked  patients  whose  EGFR  gene
tatuses  were  unknown.  The  most  common  adverse  events
f  geﬁtinib  were  rash  and  diarrhea,  which  may  cause  ter-
ination  of  treatment.  In  this  study,  we  found  that  the
ncidence  of  rash  in  geﬁtinib  plus  CHM  group  was  statistically
ower  than  that  in  geﬁtinib  group,  these  ﬁndings  indicated
hat  FZKA  can  reduce  the  toxicity  of  geﬁtinib,  the  possible
echanism  is  that  some  Chinese  herbal  medicine  such  as
 1
1
1
1
1
1
1
1Effect  of  geﬁtinib  plus  CHM  in  patients  with  advanced  NSCLC
O.  diffusa31 may  relieve  skin  rash  through  anti-inﬂammatory
effect.
The  result  of  this  case—control  study  suggested  that  CHM
(FZKA)  may  have  a  synergistic  effect  on  geﬁtinib.  How-
ever,  the  exact  mechanism  is  still  unknown,  the  possible
explanation  is  that  some  components  of  FZKA  such  as  P.
heterophylla,32 A.  membranaceus,33 O.  diffusa34 and  S.
nigrum35 have  demonstrated  anti-tumor  activity  in  human
tumor  cells.  In  vitro  study,  we  also  found  that  the  addition
of  FZKA  and  geﬁtinib  to  A549  (a  cell  line  with  low  EGFR-TKI
sensitivity)  and  H1650  (a  cell  line  with  EGFR-TKI  resistance)
cells  resulted  in  down-regulation  of  p-EGFR  and  p-MAPK,
suggesting  the  anti-proliferation  effect  on  FZKA  and  geﬁt-
inib  was  acted  through  inhibiting  the  activation  of  EGFR  and
its  downstream  pathway  Ras/Raf/MAPK  (To  be  published).
There  were  some  limitations  in  our  study.  First,  we
could  not  match  the  two  groups  completely  because  of  the
intervention  variation  in  geﬁtinib  plus  CHM  group.  Some
adjustments  were  made  based  on  the  speciﬁc  symptoms  pre-
senting  on  patients  in  geﬁtinib  plus  CHM  group,  for  example,
if  the  patient  presented  with  chest  and  back  pain,  pleu-
ral  effusion,  hemosputum  or  fever,  some  Chinese  herbal
medicines  were  added  to  relieve  the  symptoms.  However,
there  was  no  such  adjustment  in  geﬁtinib  group.  Second,  as
mentioned  above,  the  treatment  group  and  control  group
were  not  matched  completely  because  of  Chinese  herbal
medicines  micro-adjustment  in  treatment  group,  an  incom-
pletely  matched  analysis  may  partly  reduce  the  validity  of
the  case—control  comparison.
In conclusions,  this  case—control  analysis  suggested  that
treatment  with  geﬁtinib  plus  CHM  (FZKA)  prolonged  PFS  and
MST  compared  with  geﬁtinib  in  patients  with  NSCLC.  As  this
is  a  retrospective  and  non-randomized  study,  further  study
is  needed  to  conﬁrm  the  result.
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